De Lisle Partners’s Roivant Sciences ROIV Stock Holding History

De Lisle Partners’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50,000	Closed	-$504K	–	183
2025 Q1	$504K	Hold	50,000	–	–	0.08%	167
2024 Q4	$592K	Sell	50,000 -40,000	-44%	-$473K	0.09%	169
2024 Q3	$1.04M	Hold	90,000	–	–	0.17%	138
2024 Q2	$951K	Hold	90,000	–	–	0.21%	119
2024 Q1	$950K	Buy	+90,000	New	+$970K	0.22%	115

Other funds holding ROIV

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

De Lisle Partners's ROIV Position: Q2 2025 in Review

De Lisle Partners sold out of Roivant Sciences (ROIV) in Q2 2025, closing a stake of 50,000 shares — an estimated $504K sold.

De Lisle Partners first reported a position in ROIV in Q1 2024 and held it in 5 quarters. The position peaked at $1.04M in Q3 2024. 337 funds tracked by Wall St. Rank hold ROIV as of Q2 2025.

De Lisle Partners reported no remaining Roivant Sciences position as of Q2 2025 after selling out during the quarter.
De Lisle Partners sold 50,000 Roivant Sciences shares in Q2 2025, an estimated $504K.
De Lisle Partners first reported a position in Roivant Sciences in Q1 2024 and held it in 5 quarters.
De Lisle Partners's Roivant Sciences position peaked at $1.04M in Q3 2024.
337 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2025.

Based on De Lisle Partners's 13F filing for Q2 2025, filed 13 Aug 2025.